Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Fumapharm (Royalty interest in BG-12 and Fumaderm)

M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

A portfolio of royalty interests in therapeutic medicines. The portfolio comprises of BG-12, an oral therapeutic medicine for the treatment of relapsing-remitting multiple sclerosis and Fumaderm, a therapeutic medicine for the treatment of moderate to severe plaque psoriasis.

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Acquirer
Primary Office
  • Haldenstr. 24a
  • 6006 Lucerne
  • Switzerland

Fumapharm (Royalty interest in BG-12 and Fumaderm) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request full access to PitchBook

Fumapharm (Royalty interest in BG-12 and Fumaderm) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Fumapharm (Royalty interest in BG-12 and Fumaderm)‘s full profile, request access.

Request full access to PitchBook